Treatment
Nivolumab clinical trials
We’re tracking 278 recruiting studies that include Nivolumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05428007RecruitingPhase 2
Sarilumab with three immunotherapy drugs for advanced melanoma
This Phase 2 trial tests whether adding sarilumab (an immune-blocking medicine) to three immunotherapy medicines can shrink unresectable, advanced melanoma that cannot be removed with surgery. It aims to improve how well the immune system controls the cancer, especially in Stage III or Stage IV disease.
Los Angeles, CaliforniaAges 18–100 - NCT05501665RecruitingPhase 1/Phase 2
Adaptive radiation plus pembrolizumab for stage IV lung cancer
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
Nashville, TennesseeAges 18 years+ - NCT05681780RecruitingPhase 1
CD40L-treated immune cells for advanced lung cancer with certain gene changes
This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.
Tampa, FloridaAges 18 years+ - NCT05715229RecruitingPhase 2
Blood test–guided treatment choice for advanced lung cancer
This Phase 2 study tests how results from blood cancer DNA tests (ctDNA) can help choose the best immune therapy approach for newly diagnosed, advanced lung cancer. It aims to improve outcomes by matching treatment decisions to a patient’s immune and blood test “profile.”
Washington D.C., District of ColumbiaAges 18 years+ - NCT05732389RecruitingPhase 2
Immunotherapy for early rectal cancer with dMMR or MSI
This trial studies whether immunotherapy (nivolumab plus ipilimumab) can help people with early-stage rectal cancer that has dMMR or MSI changes. It’s meant for patients who have not yet had chemotherapy, radiation, or immunotherapy for colorectal cancer.
AalborgAges 18 years+ - NCT05845450RecruitingPhase 2
Pre-surgery targeted drugs for selected colorectal cancer tumors
This trial tests targeted cancer drugs given before planned colon or rectal surgery. It may help by trying to shrink the tumor and treat specific tumor “targets” found in your stored pathology sample, depending on your tumor’s genetics and marker tests.
Milan, Lombardia/MIAges 18 years+ - NCT05896839RecruitingPhase 1/Phase 2
Immunotherapy with prednisone and sirolimus for transplant skin cancer
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
La Jolla, CaliforniaAges 18 years+ - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Dublin, CaliforniaAges 18 years+ - NCT06031233RecruitingPhase 4
Shorter infusion times for cancer immunotherapy drugs
This trial tests if giving common immunotherapy drugs over a shorter time is safe. It may mean less time in the clinic for you.
ZwolleAges 18 years+ - NCT06158919Recruiting
Immunotherapy Plus Targeted Therapy and Chemo for Stomach Cancer
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06245356RecruitingPhase 2
A safety trial of trifluridine/tipiracil for DPD-deficient patients
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
AmiensAges 18 years+ - NCT06275360RecruitingPhase 2
Immunotherapy re-treatment for veterans with lung cancer
This trial tests whether restarting immunotherapy along with chemotherapy and radiation can help veterans with stage III lung cancer that cannot be removed by surgery. It's for people whose tumors have a certain protein (PD-L1) and who haven't had these treatments before for advanced cancer.
West Haven, ConnecticutAges 18 years+ - NCT06319196RecruitingPhase 2
Clearing melanoma with immunotherapy after surgery
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
Toronto, OntarioAges 18 years+ - NCT02813135RecruitingPhase 1/Phase 2
Targeted cancer treatment chosen by a tumor’s genetic findings
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
CopenhagenAges Up to 18 years - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT06364631RecruitingPhase 3
Testing a new approach for advanced kidney cancer
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
ViennaAges 18 years+ - NCT06364917RecruitingPhase 2
Comparing two immunotherapy options for PD-L1 negative lung cancer
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Birmingham, AlabamaAges 18–89 - NCT06448572RecruitingPhase 1/Phase 2
EXL01 and nivolumab for immunotherapy-resistant lung cancer
This trial tests an investigational microbiome therapy (EXL01) combined with nivolumab (an immunotherapy) for people with advanced non-small cell lung cancer whose cancer continued to grow after standard immunotherapy and chemotherapy. The goal is to see if adding EXL01 can help the immune system fight the cancer again.
LilleAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT06532149Recruiting
Sexual health and erectile function in men with lung cancer
This study looks at how lung cancer and its treatments affect men's sexual health, including erectile function and hormone levels. If you are a man with advanced lung cancer and are sexually active, researchers want to learn about your experiences and test results.
RomeAges 18–75 - NCT06490536RecruitingPhase 3
Testing a new treatment for high-risk colon cancer after surgery
This trial tests a new treatment approach for people with certain high-risk colon cancers (stage II or III in the upper colon) after surgery. It aims to see if adding a study drug can help prevent the cancer from coming back.
BerlinAges 18 years+ - NCT06519682Recruiting
Immunotherapy for young people with a specific brain tumor
This trial is testing a new immunotherapy (nivolumab) for children, teens, and young adults with a specific type of aggressive brain tumor (glioblastoma that has a DNA repair problem). It aims to see if giving this treatment early, right after surgery, can help the immune system fight the tumor.
Toronto, OntarioAges 1–25 - NCT06554613RecruitingPhase 2
Olanzapine with first-line immunotherapy for advanced lung cancer trial
This trial tests whether adding the drug olanzapine to standard first-line immunotherapy (with or without chemotherapy) can help people with advanced lung cancer that does not have an EGFR mutation. It aims to improve treatment outcomes and quality of life.
Nanchang, JiangxiAges 18–75 - NCT06638931RecruitingPhase 2
Nivolumab for rare solid tumors with high PD-L1
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
Fortaleza, CearáAges 18 years+
Common questions
- Are there clinical trials studying Nivolumab?
- Yes. Clin2 currently lists 278 recruiting studies that include Nivolumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Nivolumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Nivolumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Nivolumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.